At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 61 enrolled
Drug / intervention
AG-920 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Single-Masked, Active-Controlled, Parallel-Group Evaluation of Safety and the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution (AG-920) in a Pediatric Population
In Brief
A Phase 3 clinical trial evaluating AG-920 and Proparacaine Ophthalmic for Anesthesia, Local. Completed, enrolled 61 participants across 1 site.
Detailed Summary
A Phase 3, randomized, active-controlled, study in pediatric subjects. It is designed to evaluate the safety and anesthetic efficacy of one dose of AG-920 ophthalmic solution compared to Proparacaine Hydrochloride Ophthalmic Solution.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnesthesia, Local
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartApr 2022
First PostedApr 2022
Primary CompletionMay 2022
TodayJul 2026
First PostedApr 13, 2022
Enrollment StartApr 6, 2022
Primary CompletionMay 27, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.2 years ago
Interventions
AG-920drug
AG-920 Sterile Topical Ophthalmic Solution
Proparacaine Ophthalmicdrug
0.5% Proparacaine Hydrochloride